Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Soleno Therapeutics, Inc. (NASDAQ:SLNO) on behalf of investors who purchased securities prior to May 26, 2025. The investigation aims to determine if the company and its officers engaged in corporate wrongdoing. The firm encourages affected investors to contact them for more information, with no cost incurred by investors as they operate on a contingency fee basis.
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Soleno Therapeutics, Inc. (NASDAQ:SLNO) concerning alleged corporate wrongdoing. The firm is encouraging stockholders who purchased Soleno securities prior to May 26, 2025, and still hold them, to contact them to assist with the investigation. The investigation aims to recover investor capital and ensure corporate accountability.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therap
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Soleno Therapeutics, Inc. (NASDAQ: SLNO) on behalf of investors who purchased securities prior to May 26, 2025, and still hold them. The investigation focuses on whether Soleno and its officers or directors engaged in corporate wrongdoing. The firm encourages affected investors to contact them for more information, noting that they represent investors on a contingency fee basis.
Neurocrine Biosciences (NBIX) quantifies Soleno acquisition and VYKAT XR impact
Neurocrine Biosciences (NBIX) filed an amendment detailing the financial impact of its Soleno Therapeutics acquisition, including Soleno's 2025 and Q1 2026 financial results and pro forma combined statements. The acquisition adds VYKAT XR, valued at $2.23 billion, leading to significant amortization expenses, while pro forma revenues for 2025 reached $3.05 billion. The report also outlines a $1 billion revolving credit facility, which Neurocrine drew from and repaid shortly after closing.
Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
Neurocrine Biosciences reported a 39% year-over-year increase in total second-quarter 2026 revenue, reaching $959 million, and raised its INGREZZA net sales guidance for the full year. The company completed the acquisition of Soleno Therapeutics in May 2026, adding VYKAT XR to its portfolio, and announced positive clinical data for CRENESSITY and VYKAT XR, while also detailing future clinical milestones for 2027.
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Soleno Therapeutics, Inc. (NASDAQ: SLNO) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Soleno securities before May 26, 2025, and still hold them, to contact them to assist with the investigation. The representation of affected investors is on a contingency fee basis.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Soleno Therapeutics, Inc. (SLNO) for potential corporate wrongdoing. The firm is encouraging investors who purchased Soleno securities before May 26, 2025, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis and seeks to restore investor capital and ensure corporate accountability.
Neurocrine executive who led $2.9B Soleno deal gets new role
Neurocrine Biosciences has appointed Samir Siddhanti as its new Chief Business Officer, effective July 21, 2026. Siddhanti, who has been with Neurocrine since 2017, previously led the company's $2.9 billion acquisition of Soleno Therapeutics and will now oversee enterprise growth strategy, including business development and corporate strategy. This appointment consolidates business development and alliance management under his leadership, reflecting Neurocrine's integrated approach to growth.
Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating Soleno Therapeutics, Inc. (SLNO) for potential corporate wrongdoing, focusing on claims from investors who purchased securities before May 26, 2025, and still hold them. The firm encourages these shareholders to contact them to assist in the investigation, which is conducted on a contingency fee basis. This action aims to restore investor capital and ensure corporate accountability.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Soleno Therapeutics, Inc. (SLNO) securities who bought shares before May 26, 2025, and still hold them. The investigation aims to determine if Soleno's officers and/or directors engaged in corporate wrongdoing. The firm encourages affected shareholders to connect with them for more information and to assist in the investigation, assuring that their representation is on a contingency fee basis.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Soleno Therapeutics, Inc. (NASDAQ:SLNO) for potential corporate wrongdoing. The firm encourages investors who purchased Soleno securities prior to May 26, 2025, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Soleno Therapeutics, Inc. (SLNO) for corporate wrongdoing. The firm encourages stockholders who purchased Soleno securities prior to May 26, 2025, and continue to hold them, to assist in the investigation. The firm operates on a contingency fee basis, representing investors in securities fraud class actions.
Soleno Therapeutics (SLNO) Cantor Global Healthcare Conference 2025 Summary
This article summarizes Soleno Therapeutics' presentation at the Cantor Global Healthcare Conference 2025, highlighting the successful U.S. launch and European filing of their drug for Prader-Willi syndrome (PWS). The company reported significant patient engagement and strong financial standing, with the drug demonstrating clinical benefits in reducing hyperphagia and improving daily functioning, alongside a favorable risk-reward profile for appropriately selected patients.
Price to earnings forward of Soleno Therapeutics Inc – LS:A3DS0P
This page provides financial information for Soleno Therapeutics Inc (LS:A3DS0P), specifically its price to earnings forward. It is presented on TradingView, a platform offering market data and financial tools. The content indicates that the market for this stock is currently closed, with no trades having occurred.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Soleno Therapeutics, Inc. (NASDAQ:SLNO) regarding potential corporate wrongdoing by the company and its officers/directors. The firm is encouraging investors who purchased Soleno securities prior to May 26, 2025, and still hold them, to come forward and assist with the investigation. The representation of investors in class actions is handled on a contingency fee basis.
Ovid Therapeutics: Norrett Most Recently Served as Chief Business Officer at Soleno Therapeutics, Where He Led Company's Acquisition by Neurocrine Biosciences >OVID
Ovid Therapeutics announced the appointment of Andrew Norrett as Chief Business Officer. Norrett previously held the same position at Soleno Therapeutics, where he was instrumental in the company's acquisition by Neurocrine Biosciences. His appointment is expected to bolster Ovid's strategic growth initiatives.
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Soleno Therapeutics, Inc. (NASDAQ:SLNO) on behalf of investors who purchased shares prior to May 26, 2025. The investigation focuses on whether Soleno's officers and/or directors engaged in corporate wrongdoing. The firm encourages affected shareholders to contact them to learn more about the investigation at no cost.
Soleno Therapeutics (SLNO) Goldman Sachs 45th Annual Global Healthcare Conference summary
This article summarizes Soleno Therapeutics' presentation at the Goldman Sachs 45th Annual Global Healthcare Conference, focusing on their drug DCCR for Prader-Willi syndrome (PWS). DCCR is a once-daily pill targeting KATP channels to reduce appetite and has shown significant improvements in hyperphagia and behavioral symptoms in clinical trials. The company also highlights upcoming product launches and strong market penetration for VYKAT XR (likely DCCR's brand name) in the PWS treatment landscape.
Soleno Therapeutics (SLNO) Q4 2025 earnings summary
Soleno Therapeutics reported strong Q4 and full-year 2025 results, driven by the successful commercial launch of VYKAT XR, an FDA-approved therapy for Prader-Willi syndrome. The company achieved profitability in 2025 with $190.4 million in net revenue and ended the year with 859 active patients and over 185 million lives covered. Soleno Therapeutics plans to expand market penetration, evaluate EU regulatory decisions for DCCR, and initiate new clinical programs in 2026.
Soleno Therapeutics (SLNO) Jefferies London Healthcare Conference 2024 Summary
This article summarizes Soleno Therapeutics' presentation at the Jefferies London Healthcare Conference 2024, focusing on their drug DCCR for Prader-Willi syndrome (PWS). Key points include the regulatory progress of DCCR in the US and EU, its strong clinical trial results, and the company's comprehensive commercialization strategy targeting a significant market opportunity. The summary also touches upon intellectual property, stakeholder engagement, and future market expansion plans.
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Steady Performance with Limited Upside in the Biotech Sector
Soleno Therapeutics (SLNO) is a biotech company focused on rare diseases, with its lead product VYKAT XR targeting Prader-Willi Syndrome. Despite a strong Return on Equity (26.38%) and over $91 million in free cash flow, analyst ratings suggest a cautious outlook with an average target price mirroring the current trading price. The stock is considered suitable for long-term investors willing to navigate the uncertainties inherent in the biotechnology sector, with future catalysts potentially stemming from clinical trial results and regulatory updates.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Soleno Therapeutics, Inc. (SLNO) for potential corporate wrongdoing. The firm encourages investors who purchased Soleno securities before May 26, 2025, and continue to hold them, to connect and assist with the investigation. The investigation aims to restore investor capital and ensure corporate accountability, with no cost to Soleno investors unless the firm is successful in court.
Soleno Therapeutics (SLNO) Piper Sandler 36th Annual Healthcare Conference Summary
This article summarizes Soleno Therapeutics' presentation at the Piper Sandler 36th Annual Healthcare Conference. Key points include an FDA PDUFA date extension for their Prader-Willi Syndrome (PWS) treatment, DCCR, to March 27, 2026, with an expectation for a label covering PWS patients aged four and above. The company estimates a market of about 10,000 diagnosed PWS patients in the U.S. and is preparing for a U.S. launch with a 30-person sales force, while also targeting European regulatory filings.
Soleno Therapeutics withdraws European application for PWS treatment
Soleno Therapeutics has withdrawn its marketing authorization application for VIOKAT in Europe, citing business and strategic considerations. The decision allows the company to re-engage with regulators later if a suitable pathway emerges. The withdrawal follows Neurocrine Biosciences' acquisition of Soleno for $53 per share, which prompted several analyst downgrades for Soleno but an upgraded price target for Neurocrine.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Soleno Therapeutics, Inc. (SLNO) concerning potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Soleno securities before May 26, 2025, and still hold them, to join the investigation. This investigation aims to restore investor capital and ensure corporate accountability.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Soleno Therapeutics, Inc. (NASDAQ:SLNO). The firm encourages investors who purchased Soleno securities before May 26, 2025, and still hold them, to join the investigation. The investigation aims to restore investor capital and ensure corporate accountability, with the firm representing investors on a contingency-fee basis.
Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating Soleno Therapeutics, Inc. (NASDAQ:SLNO) on behalf of shareholders who purchased securities before May 26, 2025, concerning potential corporate wrongdoing by the company's officers and directors. The law firm encourages affected investors to contact them to assist with the investigation, emphasizing that their representation is on a contingency fee basis. Peretz Bronstein, founding partner, highlighted the firm's focus on restoring investor capital and ensuring corporate accountability.
Soleno Therapeutics Inc (SLNO) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Soleno Therapeutics Inc (SLNO), highlighting major institutional investors and their holdings. It breaks down shareholder types and provides a historical overview of institutional shareholding changes, including the number of institutions, shares held, and proportional changes over several quarters. Key shareholders like Fidelity Management & Research Company LLC and Wellington Management Company, LLP are listed with their respective equity proportions and recent changes.
Soleno Therapeutics Inc (SLNO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Soleno Therapeutics Inc (SLNO). It indicates that relevant data for business segments, and regional and profit contribution for FY2025, FY2025Q4, FY2025Q3, and FY2025Q2 have not yet been disclosed by the company. The article only notes a United States revenue of $190.41 million with 0.00% proportion from a 'By Region' section, without further context.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Soleno Therapeutics, Inc. (SLNO) shareholders who purchased securities before May 26, 2025, and still hold them. The investigation focuses on whether Soleno's officers and/or directors engaged in corporate wrongdoing. The firm encourages affected investors to contact them for more information, emphasizing that they operate on a contingency fee basis.
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
Soleno Therapeutics presented new data at ENDO 2026 showing that VYKAT® XR (diazoxide choline) provides meaningful and durable improvements in hyperphagia and behavioral symptoms in patients with Prader-Willi Syndrome (PWS), even after a randomized withdrawal period. Participants who resumed treatment experienced improvements as early as Week 13, continuing for up to two years. The data also highlighted sustained benefits for up to three years compared to real-world information from the PATH for PWS Natural History Study.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Soleno Therapeutics, Inc. (NASDAQ:SLNO) and some of its officers and directors. The law firm is encouraging shareholders who purchased Soleno securities before May 26, 2025, and still hold them, to come forward and assist with the investigation. The firm operates on a contingency fee basis, meaning investors will not incur costs unless the firm is successful in recovering funds.
3-year VYKAT XR trial eases hyperphagia, behaviors in PWS
Soleno Therapeutics, a Neurocrine Biosciences company, presented new Phase 3 data at ENDO 2026 for VYKAT XR (diazoxide choline), demonstrating significant and sustained improvements in hyperphagia and behavioral symptoms associated with Prader-Willi syndrome over three years. Participants who restarted VYKAT XR after a 16-week randomized withdrawal period showed durable benefits in hyperphagia and behaviors, while continuous treatment maintained these improvements. The study also highlighted the drug's efficacy compared to natural history controls and stable BMI over two years.
Soleno Therapeutics Announces Late-Breaking Data At Endo 2026
Soleno Therapeutics presented new data at ENDO 2026 regarding its drug VYKAT® XR for Prader-Willi syndrome. The data demonstrated that resuming VYKAT XR after a randomized withdrawal period led to significant and sustained improvements in hyperphagia and behavioral symptoms over two years. Participants who continued uninterrupted therapy also maintained these durable benefits, reinforcing the drug's efficacy for long-term management of PWS.
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
Soleno Therapeutics, a Neurocrine Biosciences company, presented new data at ENDO 2026 showing that VYKAT® XR (diazoxide choline) provided durable and meaningful improvements in hyperphagia and behavioral symptoms in patients with Prader-Willi syndrome (PWS). Participants who resumed VYKAT XR after a 16-week randomized withdrawal period regained treatment benefits, with sustained improvements observed for up to two years. The data also demonstrated statistically significant and sustained improvements compared to natural history data from the PATH for PWS study, strengthening VYKAT XR's profile as a long-term treatment option for PWS.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Soleno Therapeutics, Inc. (NASDAQ:SLNO) regarding potential corporate wrongdoing by its officers and directors. The law firm is encouraging investors who purchased Soleno securities prior to May 26, 2025, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis and seeks to recover investor capital and ensure corporate accountability.
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Soleno Therapeutics, Inc. (NASDAQ: SLNO) for alleged corporate wrongdoing by its officers and/or directors. The firm is encouraging shareholders who purchased Soleno securities prior to May 26, 2025, and still hold them, to contact them to assist in the investigation. The representation is on a contingency fee basis, meaning no upfront cost to investors.
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring the Healthcare Biotech Leader’s Steady Trajectory
Soleno Therapeutics, Inc. (SLNO), a biotech company focused on rare diseases and a subsidiary of Neurocrine Biosciences, is highlighted for its lead product candidate VYKAT XR targeting Prader-Willi Syndrome. The article analyzes SLNO's stock performance, noting its current trading price of $53.01, a $2.76 billion market cap, and strong financial health with a 26.38% return on equity and over $91 million in free cash flow. While analysts currently rate it as a "hold" with a target price of $53.00, technical indicators suggest a bullish short-term trend, though it's nearing overbought territory.
NBIX: Multi-product growth, major acquisition, and robust pipeline drive strong financial and patient impact
Neurocrine Biosciences (NBIX) is undergoing a significant transformation into a multi-product, high-growth company with strong cash flow and diversified revenue. This growth is driven by the recent acquisition of Soleno Therapeutics, which expands its rare endocrine franchise, and robust R&D investments supporting a broad pipeline. The information is based on an AI-generated summary from the company's 46th Annual William Blair Growth Stock Conference Audio Transcript from June 2, 2026.
[15-12G] SOLENO THERAPEUTICS INC SEC Filing
This article reports on Soleno Therapeutics Inc.'s SEC Form 15-12G filing, which certifies the termination of registration under Section 12(g) of the Securities Exchange Act of 1934 or suspension of duty to file reports. The filing dated May 28, 2026, indicates that the company now has only one holder of record. Darin M. Lippoldt, President and Secretary, signed the certification.
[EFFECT] SOLENO THERAPEUTICS INC SEC Filing
This article reports on an EFFECT SEC filing by Soleno Therapeutics Inc. (SLNO), indicating its neutrality for both filing impact and sentiment. The filing, a Notice of Effectiveness, was dated May 27, 2026, with an accession number of 0001193125-26-234441 and submission type POS AM. The company operates in the Biotechnology industry within the Pharmaceutical Preparations sector and is headquartered in Redwood City, United States.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC announced an investigation into Soleno Therapeutics, Inc. (SLNO) for potential corporate wrongdoing. The firm encourages Soleno stockholders who purchased securities before May 26, 2025, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Soleno Therapeutics (SLNO) Investor Outlook: Navigating the Hold Ratings with Promising EPS and Cash Flow
Soleno Therapeutics (NASDAQ: SLNO) is a biopharmaceutical company focused on rare disease treatments, with a lead candidate VYKAT XR for Prader-Willi Syndrome. Despite current "hold" ratings from analysts and a static stock price, the company demonstrates strong financial health with impressive EPS of 1.93 and $91.67 million in Free Cash Flow. While the market adopts a cautious "wait-and-see" approach, Soleno's solid financial metrics and innovative potential suggest a promising long-term outlook for investors willing to ride out its developmental phase.
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Soleno Therapeutics, Inc. (NASDAQ:SLNO) regarding potential corporate wrongdoing. The firm is encouraging stockholders who purchased Soleno securities before May 26, 2025, and still hold them, to contact them to learn more about the investigation and assist in their claims. This investigation aims to restore investor capital and ensure corporate accountability.
Soleno Therapeutics (NASDAQ: SLNO) deregisters 3,000,000-share resale after merger
Soleno Therapeutics has filed a post-effective amendment to deregister a 3,000,000-share resale, confirming the termination of the registration following its merger into Neurocrine Biosciences. The amendment addresses an administrative filing error and formally removes all unsold or unissued securities under Registration No. 333-275120 as of May 21, 2026. This action eliminates the registered resale capacity and is a procedural step subsequent to the merger agreement dated April 5, 2026.
Soleno (SLNO) director’s shares cashed out at $53 per-share merger price
Soleno Therapeutics director Matthew Pauls disposed of his equity stake, consisting of 10,491 common shares and a 9,063-share stock option, as part of a merger where Soleno became a wholly owned subsidiary of Neocrine Biosciences. All shares, RSUs, and options were converted into the right to receive $53.00 in cash per share. This transaction was not an open-market sale but rather a standard cash-out process due to the acquisition.
Soleno Therapeutics (Nasdaq:SLNO) - Stock Analysis
This article provides a stock analysis of Soleno Therapeutics (Nasdaq:SLNO), detailing its valuation, future growth prospects, past performance, and financial health. Key recent updates include its acquisition by Neurocrine Biosciences, Inc. for $2.8 billion, a securities class action lawsuit regarding its DCCR program, and various changes in executive leadership and financial forecasts. The company's lead product, VYKAT XR, for Prader-Willi Syndrome, recently received FDA approval and commercial availability.
Soleno Therapeutics (NASDAQ: SLNO) deregisters S-3 after Neurocrine merger
Soleno Therapeutics (NASDAQ: SLNO) has filed a post-effective amendment to deregister all unsold securities previously registered under Form S-3. This action follows the completion of a merger on May 18, 2026, which resulted in Soleno becoming a wholly owned subsidiary of Neurocrine Biosciences, Inc. The deregistration terminates the effectiveness of Registration Statements Nos. 333-275120 and 333-276344, removing any remaining unsold securities.
Soleno Therapeutics (SLNO) CFO has RSUs and stock options cashed out in Neocrine merger
Soleno Therapeutics' CFO, Jennifer Fulk, had her restricted stock units (RSUs) and stock options cashed out as part of Soleno's merger into a wholly owned subsidiary of Neocrine Biosciences. A total of 39,200 RSU shares and an employee stock option covering 67,660 shares were cancelled, with RSU holders receiving $53.00 per share in cash and option holders receiving a cash payment based on the difference between the merger consideration and the exercise price. After these transactions, Fulk holds no remaining equity from these awards.
Soleno Therapeutics (NASDAQ: SLNO) taken private at $53 per share in cash deal
Neurocrine Biosciences has completed its acquisition of Soleno Therapeutics (NASDAQ: SLNO) for $53.00 per share in cash, with approximately 88.9% of shares tendered. Following the tender offer, Soleno merged into Neurocrine's subsidiary on May 18, 2026, becoming a wholly owned subsidiary. As a result, Soleno will be delisted from Nasdaq, deregistered with the SEC, and its previous loan agreement and employee stock purchase plan have been terminated.
